Media stories about Prana Biotechnology (NASDAQ:PRAN) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prana Biotechnology earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.6895960747654 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Prana Biotechnology (NASDAQ PRAN) traded down $0.06 during mid-day trading on Monday, hitting $3.39. The stock had a trading volume of 56,600 shares, compared to its average volume of 152,311. Prana Biotechnology has a twelve month low of $1.52 and a twelve month high of $4.58.
Separately, ValuEngine upgraded Prana Biotechnology from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th.
Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders.
Receive News & Ratings for Prana Biotechnology Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology Ltd and related companies with MarketBeat.com's FREE daily email newsletter.